PharmaShots | Incisive News in 3 Shots

Subscribe Now

pembrolizumab

Bio-Thera Solutions Reports the Initiation of Combined P-I/P-III Study of BAT3306 (Biosimilar, Keytruda)

Bio-Thera Solutions Reports the Initiation of Combined P-I/P-III Study of BAT3306 (Biosimilar, Keytruda)

July 25, 2024

Samsung Bioepis Reports the Initiation of the P-I Trial Evaluation of SB27 (biosimilar, pembrolizumab) for the Treatment of Lung Cancer

Samsung Bioepis Reports the Initiation of the P-I Trial Evaluation of SB27 (biosimilar, pembrolizumab) for the Treatment of Lung C...

March 4, 2024

Merck’s Keytruda (pembrolizumab) in Combination with Chemotherapy Receives CHMP’s Positive Opinion for the Treatment of Non-Small Cell Lung Cancer

Merck’s Keytruda (pembrolizumab) in Combination with Chemotherapy Receives CHMP’s Positive Opinion for the Treatment of Non-Small...

February 23, 2024

Astellas Receives the EMA’s Validation on Type II Variation Application for Padcev (enfortumab vedotin) in Combination with Keytruda (pembrolizumab) to Treat Advanced Bladder Cancer

Astellas Receives the EMA’s Validation on Type II Variation Application for Padcev (enfortumab vedotin) in Combination with Keytru...

January 29, 2024

Merck Reports Results for Keytruda (pembrolizumab) in P-III Trial as an Adjuvant Therapy for Urothelial Carcinoma

Merck Reports Results for Keytruda (pembrolizumab) in P-III Trial as an Adjuvant Therapy for Urothelial Carcinoma

January 29, 2024

Moderna and Merck Report Results from the P-IIb (KEYNOTE-942) Study of mRNA-4157 (V940) + Keytruda (pembrolizumab) for Resected High-Risk Melanoma

Moderna and Merck Report Results from the P-IIb (KEYNOTE-942) Study of mRNA-4157 (V940) + Keytruda (pembrolizumab) for Resected Hi...

December 15, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us